<h4>Objective</h4>This study aimed to assess the latent threat of depression and suicide/self-injury associated with the combination of glucagon-like peptide-1 agonists (GLP-1RAs) and metformin versus GLP-1RAs monotherapy, through analyzing the data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).<h4>Methods</h4>We systematically searched the FAERS database for reports on the concomitant use of GLP-1RAs and metformin compared with the GLP-1RAs monotherapy in diabetic or obese patients. The gene discussed is GCG; the disease is depressive symptom measurement.